VEGF-A splicing: the key to anti-angiogenic therapeutics?
about
AVISPA: a web tool for the prediction and analysis of alternative splicingFunctional Translational Readthrough: A Systems Biology PerspectiveAlternative RNA splicing: contribution to pain and potential therapeutic strategyBiomarkers of Angiogenesis in Colorectal CancerThe cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysisSplicing Regulators and Their Roles in Cancer Biology and TherapyCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Splice isoforms as therapeutic targets for colorectal cancerTherapeutic angiogenesis: controlled delivery of angiogenic factors.Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic NephropathySpecific and Modular Binding Code for Cytosine Recognition in Pumilio/FBF (PUF) RNA-binding DomainsSpecific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative SplicingSerine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancerAlternative pre-mRNA splicing regulation in cancer: pathways and programs unhingedTranscriptional regulation of VEGFA by the endoplasmic reticulum stress transducer OASIS in ARPE-19 cellsRegulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesisPotential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340)VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyOverexpression of VEGF165b in podocytes reduces glomerular permeability.Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies.Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosisThe herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization.RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of VEGFAxxxb isoforms.Anticipatory affect: neural correlates and consequences for choiceEffect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.Let it flow: Morpholino knockdown in zebrafish embryos reveals a pro-angiogenic effect of the metalloprotease meprin alpha2.Recombinant human VEGF165b inhibits experimental choroidal neovascularizationTranscriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response.Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.TNF-α-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulationRefining orthologue groups at the transcript level.Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Expression profiling after activation of amino acid deprivation response in HepG2 human hepatoma cellsTherapeutic potential of manipulating VEGF splice isoforms in oncologyVEGF in the lung: a role for novel isoformsThe role of mRNA splicing in prostate cancer.
P2860
Q21183995-330968FD-BEA0-4678-8793-1C86D0A60756Q26739061-CE45B7CE-8074-4F5B-BC68-9BE8E87B559FQ26744085-0B624EF0-D002-4BC6-8153-0B13231229D2Q26778891-C8B4B348-7613-4052-AD40-D6255B00EC9CQ26796921-0246E8BA-A2FD-46F3-AEBF-4077B478E600Q26798158-5C97D559-3A14-4213-B877-75BE05C35255Q26823757-C3A39465-A0BB-41E8-ABB2-6CBB4DAF53CCQ27000351-B7639E77-1AF1-4B82-89B5-B0B6783ABBB5Q27006500-A7AE2DFA-48A7-47E5-B9A1-494E20C3D45EQ27023731-2377B2B0-DEBB-4F0D-A88D-71546925CC29Q27342809-48C86436-F8CD-4E98-B24A-D51EBF3ED7AAQ27666276-57BC9E84-E124-4FE8-B617-609DDF6E9650Q27666758-552D9983-EC56-4CCE-9A2A-E6F2806E86D9Q28251240-D48FD2DA-BC8E-4BB1-A1C3-F13C28EF94F5Q28297381-A4DCF51C-C378-485B-8B20-41B95C28061BQ28485361-5259AF05-D3BB-4796-9523-D15712AF4778Q28513991-C7A59AE4-8E4B-49C3-955C-157E39F4D1AEQ28547020-6AA22995-1CE5-41DF-9194-A549E457CBF3Q30275233-8393B310-7848-439F-94D7-89099EE4DD11Q30437567-2A79FE79-3705-4BFC-850D-BE6BAD4A3242Q30455612-46DFABEE-ECA1-4380-A542-9E0EBF6122B0Q30497786-DEF2B786-1A1F-408C-B8F2-D74DDD105063Q30653662-F20A277C-1F93-4CFF-A40F-A9C83E616869Q30671049-54FDC49B-9D3C-4F31-A986-B712051627D5Q30912245-99D0FE95-145E-47A7-BF78-0714216873E4Q31036498-9E58B967-EA1A-400A-9EDB-E1229B94BF55Q31168175-A631F1F7-06CA-4F2A-B41A-86E58C282705Q33373233-248D0072-EBE1-4FFE-94C0-5E6C39249DCEQ33487136-217D742E-8AC6-4466-9B48-D30895E0476CQ33526257-BA646D73-692B-4B86-8B2B-D5E86C43DDCEQ33541827-C591FAD5-E299-4C7A-A094-91CC74A47A77Q33686864-7FCD3366-5CB7-445B-B324-53D87049435EQ33742338-2295FC06-FE49-4143-9298-4A7664CC140AQ33753821-5989B498-2C0F-4727-BA6F-0ED584AC43B2Q33766662-D4A62E16-C475-4953-BEE0-10A4A7977BC3Q33828636-AFDCBF82-1D67-4428-913E-DDEDF8D32D71Q33847650-F5636507-424F-4E43-95A5-9D67BBD03416Q33888458-B1BB76A7-50AE-4E79-83A3-A363D205C4D0Q33916926-3FA62FD8-6D03-4AA8-8B76-96D6899E2A43Q33922376-6D7F4F69-EDA3-4B08-8335-FA0C7EDE56D1
P2860
VEGF-A splicing: the key to anti-angiogenic therapeutics?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@en
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@nl
type
label
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@en
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@nl
prefLabel
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@en
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@nl
P2860
P356
P1476
VEGF-A splicing: the key to anti-angiogenic therapeutics?
@en
P2093
David O Bates
Steven J Harper
P2860
P2888
P304
P356
10.1038/NRC2505
P407
P577
2008-10-16T00:00:00Z